Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Faruqi & Faruqi, LLP Launches Investigation Against NeoStem Inc
Faruqi & Faruqi, LLP, a national securities firm headquartered in New York City, is investigating the Board of Directors of NeoStem Inc (NeoStem or the Company) for potential breaches of fiduciary duties in connection with their conduct of seeking shareholders’ approval of the compensation for the Company’s named executive officers. The terms of the compensation to be awarded to the Company’s executive officers are outlined in the Proxy Statement on Form Schedule 14A that the Company filed with the Securities and Exchange Commission on September 7, 2012.
Latest Developments for NeoStem Inc
Latest Key Developments in Biotechnology
- Oramed Pharmaceuticals Inc Receives FDA Clearance To Initiate Oral Insulin Trials In U.S.
- Cordlife Group Ltd Announces Proposed Acquisition Of CS Cell Technologies Pte. Ltd, Cordlife Stem Cell Technology Limited And Certain Assets Of P.T. Cordlife Indonesia From Cordlife Limited
- Stemline Therapeutics Inc Prices $60 Million Public Offering Of Common Stock
- Ambit Biosciences Corp Announces Pricing Of Initial Public Offering
- Share this
- Link this
- Digg this
Follow Reuters